# Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

Canonical page: https://grantsonar.com/grants/opportunity/amyotrophic-lateral-sclerosis-als-intermediate-patient-population-expand-029d2216-e9ee-417e-8fee-fea203f0b887
Source: grants_gov
Source ID: 360400
Last confirmed Oct 13, 2026 · Grants.gov
Deadline: November 10, 2026
Award size: not disclosed

## Answer-first Q&A

### Who is eligible for Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)?

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) eligibility includes eligible applicants named in the notice. Geographic eligibility is national or notice-specific geography; applicants should confirm the source notice before applying.

### What is the deadline for Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)?

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) has a listed deadline of November 10, 2026. Grant deadlines can change, so verify the current date with National Institutes of Health before submitting.

### How much funding is available for Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)?

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) lists an award size of not disclosed. Award ranges and total program funding are reported from the source metadata when available.

### Who funds Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)?

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) is funded by National Institutes of Health. GrantSonar tracks the notice with source ID 360400 from grants_gov.